DIAH

DIAH 2026

19 – 21 May 2026 | Bruges, Belgium

ProductUpdated on 22 April 2026

Entry portal through the intestinal barrier

Sven ARNOUTS

Business Development Manager at Ghent University - provaxs

Merelbeke, Belgium

About

Controlled transfer of biological compounds through the intestinal (mucosal) barrier via targeting of the compound to a defined receptor (APN) on the epithelium.

Via selective transcytosis through the intestinal barrier various functions at the level of the intestinal epithelium and beyond can be modulated: i) antigens can be efficiently presented to the gut associated lymphoid tissue (GALT) leading to a protective mucosal immune response and ii) drugs or drug-containing (nano-)particles can be transferred and delivered across the intestinal barrier.

Proof of concept for oral vaccination in the pig

Oral immunization of pigs with rabbit anti-APN antibodies leads to higher antibody responses when compared to immunization with a control rabbit antibody.

Partnering

We seek partners for licensing specific applications of our targeting technology and investors for a new start-up on the targeting technology platform.

Looking for

  • Commercial Partner
  • Strategic Partner
  • Industry Partner
  • Technology Partner
  • Licensing Partner
  • Investor
  • Manufacturing Partner

Applies to

  • Animal Health Biotechnology
  • Veterinary Vaccines
  • Livestock Farming
  • Antimicrobial Resistance Solutions

Organisation

Ghent University - provaxs

Merelbeke, Belgium

Similar opportunities

  • Expertise

    Accelerating Animal Health R&D through Biological Intelligence

    • Diagnostics Development
    • AI & Predictive Analytics
    • Biotechnology & Life Sciences
    • Digital Health & Data Science
    • Clinical & Veterinary Research
    • Agritech & Precision Livestock
    • Translational & Applied Research
    • Epidemiology & Infectious Disease

    Alexander Koch

    Scientific engagement manager at BioLizard

    Brussels, Belgium

  • Product

    A probiotic to improve udder health

    • Industry Partner
    • Strategic Partner
    • Licensing Partner
    • Livestock Farming
    • Commercial Partner
    • Technology Partner
    • Veterinary Therapeutics
    • Animal Health Biotechnology
    • Sustainable Livestock Health
    • Antimicrobial Resistance Solutions

    Sven ARNOUTS

    Business Development Manager at Ghent University - provaxs

    Merelbeke, Belgium

  • Product

    Nanobody-based biologics

    Nicolás Galmarini

    CEO & Co-founder at NanoVet Biotech

    Pamplona, Spain